SERUM LEVELS OF TUMOR NECROSIS FACTOR (TNF-A) AND ITS SOLUBLE RECEPTORS STNF-R1 AND STNF-R2 IN CANCER PATIENTS


Cite item

Full Text

Abstract

The paper presents the results of investigating the balance of the proinflammatory cytokine TNF-α and its soluble receptors in the sera of patients with different kinds of solid tumors. As compared with donors, the patients showed a shift in the serum level distribution of TNF-а and its soluble receptors sTNF-R1 and sTNF-R2 towards higher values. This shift was most pronounced in patients with gastric or colorectal cancer and least in those with squamous cell carcinoma of the head and neck. Lung cancer and melanoma were intermediate. In the cancer patients, the correlation was found to remain between the serum levels of TNF-α and its receptors, which was similar to that in the donors. However, a number of patients (with all tumor sites in question) were observed to have an imbalance between the serum levels of TNF-α and sTNF-R1 due to a greater proportion of cases with both a low and high sTNF-RUTNF-α ratio.

About the authors

V. I. Chissov

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

дир. - акад. РАМН

N. S. Sergeyeva

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

N. V. Marshutina

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

канд. биол. наук, ст. науч. сотр. отд-ния прогноза эффективности консервативного лечения 125284, Москва, 2-й Боткинский пр., 3

E. V. Filonenko

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

M. P. Solokhina

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

E. V. Zenkina

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

P. A. N. A. Parilova

Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of Russia

References

  1. Навашин С. М., Вядро М. М. // ВИНИТИ. Итоги наукии техники. Сер.: Онкология. 1989. С. 1-86.
  2. Фрейдлин И. С. // Тихоокеан. мед. журн. "Дальнаука". 1999. № 3. С. 13-19.
  3. Чиссов В. И., Сергеева Н. С., Маршутина Н. В.и др. // Рос. онкол. журн. 2009. № 6. С. 28-31.
  4. Чиссов В. И., Сергеева Н. С., Маршутина Н. В.и др. // Рос. онкол. журн. 2009. № 6. С. 50-51.
  5. Fuksiewicz M., Kaminska J., Kowalska M. et al. // Tumor Biol. 2007. Vol. 28 (suppl. 1). P 93.
  6. Ichim Ch. V // J. Trasl. Med. 2005. Vol. 3. P. 8.
  7. Lentz M. R., Hubbard W., Fisher C. // Jpn. J. Apher. 1997. - Vol. 16. P 107-114.
  8. Lentz M. R. // Ther. Apher. 1999. Vol. 3. P. 40-49.
  9. Lentz M. R., Kumar K. // Ther. Apher. Dial. 2008. Vol. 12, N 6. P. 491-496.
  10. Mitsiades C. S., Poulaki P., Mitsiades N. // J. Endocrinol. 2003. Vol. 78. P 205-216.
  11. Petak I., Houghton J. // Pathol. Oncol. Res. 2001. Vol. 7, N 2. P. 106.
  12. Selinsky C. L., Howel M. D. // Cell Immunol. 2000. Vol. 200. P. 81-87.
  13. Van Horssen R., ten Hagen T. L. M., Eggermont A. M. // Oncologist. 2006. Vol. 11. P. 397-408.

Copyright (c) 2012 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies